Treatment for a pandemic an ongoing search by K. S., Srikanth
56 — Rediscovering School Science | Oct 2020
The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has affected millions around 
the globe, and caused thousands of 
deaths. Until large-scale vaccination 
becomes a possibility, the outbreak is 
being managed through public health 
measures to slow the spread of infection 
and supportive measures to treat the 
infected. How do we treat a disease 
caused by a ‘novel’ pathogen?
Approaches to treatment
Not everyone infected with COVID-19 
requires treatment. The immune 
response that SARS-CoV-2 virus triggers 
in our body is, in most cases (~ 81% of 
people), enough to resolve the infection 
with no (asymptomatic), or a few mild 
symptoms. More severe or critical 
symptoms are seen only when damage 
caused by the virus is combined with 





FOR A PANDEMIC: AN ONGOING 
SEARCH
Is there a cure for 
COVID-19? Does everyone 
with the disease require 
treatment? At what 
stage of infection does 
treatment become 
essential? What are the 
different approaches 
that are used to treat 
COVID-19 patients? 
What are some of the key 
concerns, side-effects, 
and limitations of each 
approach?
Based on how host-virus interactions 
correlate with clinical symptoms, 
three phases of COVID-19 disease 
progression have been proposed 
— an incubation or early infection 
phase, a pulmonary phase, and a 
hyperinflammatory phase (see Fig. 1). 
While these phases can show much 
overlap, their identification can help 
in more effective treatment. For 
example, containment of the virus 
would be more important in the first 
phase, whereas immunosuppressive 
treatment would be more helpful in 
the second and third phases. 
As of now, no specific drug is known 
to prevent or treat this infection. 
But researchers across the world 
are working on two strategies — 
designing new drugs, and repurposing 
existing drugs (see Box 1). Based on 
how they act, these pharmacological 
approaches are of two kinds:
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 z Those that target the novel virus: 
This includes drugs that prevent viral 
invasion, and protect host cells from 
infection. For example, inhibitors of 
cellular enzymes (like proteases and 
furins) help prevent the assembly of 
new viruses, while endosomal entry 
inhibitors may prevent the entry of the 
virus into host cells. Drugs affecting 
viral replication can prevent the spread 
of infection within our body. 
 z Those that can help treat symptoms 
of the disease: This includes drugs that 
can reduce disease severity and risk of 
death. For example, people with ongoing 
inflammation (due to hypertension, 
cardiovascular conditions, or diabetes) 
tend to be at greater risk of developing 
severe illness. Also, severe cases of 
COVID-19 show a strong inflammatory 
response (hyperinflammatory phase) 
with an overwhelming release of 
cytokines (called a cytokine storm). 
This plays a critical role in respiratory 
failure. Drugs that target this irregular 
inflammatory response can help manage 
such symptoms.
Antiviral drugs
Unlike antibiotics (which act against 
bacteria), antiviral drugs do not 
‘kill’ the virus. They only inhibit its 
development within the host, giving the 
host’s immune system time to mount 
a response against the virus. Most 
antiviral drugs are directed against 
virus-specific replication processes. 
Since virus replication occurs within 
host cells and uses the host cellular 
machinery, the challenge is to develop 
drugs that inhibit the virus without 
harming the host. Hence, drugs against 
other coronaviruses like SARS-CoV 
and MERS-CoV, or viruses like HIV, are 
being explored for COVID-19 treatment. 
Repurposing antivirals is not simple — a 
drug that works against SARS-CoV or 
MERS-CoV may not necessarily work 
against SARS-CoV-2. Despite these 
limitations, antivirals like remdesivir, 
lopinavir-ritonavir, favipiravir, tenofovir, 
and ribavirin have shown some 
promising results against SARS-CoV-2 
(see Box 2). Clinical trials will help 




This approach, also known as 
Therapeutic Plasma Exchange 
(TPE), was found to be useful during 
the SARS pandemic. It is based on 
Box 1. New and old drugs:
The design of new drugs is affected 
by limitations in our understanding 
of SARS-CoV-2 biology, and the 
host-pathogen interactions that 
lead to COVID-19. Also, the process 
of drug development, like that of 
new vaccines, is expensive, time-
consuming, and has a very low 
success rate. Some reports suggest 
that only 1 out of 10,000 preclinical 
compounds reaches the market.1 In 
contrast, repurposing existing drugs 
(developed against similar viruses, or 
with the ability to treat the same/
related symptoms) requires tests 
for safety and efficacy in treating 
different disease phases. Since this is 
relatively faster, many existing drugs 
and treatment regimens are currently 
undergoing clinical trials.
Fig. 1. COVID-19 progression with common symptoms and likely treatment strategies. Each 
phase is characterized by a different type of biological interaction between SARS-CoV-2 and 
the body’s immune response. In Phase I, or the early infection or incubation phase, the 
SARS-CoV-2 virus infects cells in the respiratory tract, replicates within them, and releases 
new viral particles. In Phase II, or the pulmonary phase, the infection reaches the lungs and 
the body’s immune system is strongly affected by it. In Phase III, or the hyperinflammatory 
phase, the virus moves from the lungs to the blood, reaching and infecting other body organs. 
The body’s response against the virus is amplified to an extent where it may cause injury to its 
own organs. All three phases are seen only in severe cases.
Credits: Adapted from an image by Romagnoli S., Peris A., De Gaudio A.R & Geppetti P. in ‘SARS-CoV-2 
and COVID-19: From the Bench to the Bedside’. Physiological Reviews. URL: https://doi.org/10.1152/
physrev.00020.2020. 
58 — Rediscovering School Science | Oct 2020
the principle that a person who 
has recovered from a COVID-19 
infection would have neutralizing 
immunoglobulins (antibodies) against 
SARS-CoV-2 in their blood plasma 
(convalescent plasma). When this 
plasma (the liquid part of blood minus 
the blood cells) is transferred to an 
infected person, the anti-SARS-CoV-2 
antibodies would neutralize the virus 
in the recipient (see Fig. 2). 
The challenge for this therapy lies in 
finding healthy donors with high titres 
of neutralizing antibodies. The plasma 
donors need to have had COVID-19, 
but been completely symptom-free for 
at least 14-28 days before donation. 
They need to test negative for 
COVID-19, and have high SARS-CoV-2 
neutralizing antibody titres. They 
also need to be healthy enough to 
donate plasma. The potential risks of 
convalescent plasma therapy include 
transfusion-related allergic reactions 
and pathogen transmission.5
Preliminary studies have shown a 
decrease in nasopharyngeal SARS-
CoV-2 viral load, reduction in COVID-19 
disease severity, and improved blood 
oxygenation after 12 days of CPT.6 
However, these studies are limited by 
small sample sizes and lack of robust 
data. In India, the ICMR has approved 
a multicentric phase-II clinical trial to 
test the efficacy of CPT on COVID-19 
patients with moderate illness.
Drugs against other 
pathogens
Drugs against other pathogens can 
act in ways that could help treat 
viral infections. For example, the 
antimalarial drugs chloroquine and 
hydroxychloroquine, the antiparasitic 
drug ivermectin, and the antibiotic 
azithromycin are now being studied for 
anti-SARS-CoV-2 activity (see Box 3).
Monoclonal antibodies/
IL-6 pathway inhibitors
In critically ill patients, mild or severe 
cytokine release syndrome (CRS) could 
lead to Acute Respiratory Distress 
Syndrome (ARDS). A cytokine can only 
act on a cell if it can bind to specific 
membrane receptors, and drugs like 
tocilizumab, itolizumab, sarilumab, and 
siltuximab can inhibit these receptors. 
Thus, the DCGI has approved the use 
of tocilizumab, and a similar drug 
itolizumab, for emergency use in 
severe COVID-19 patients. Tocilizumab 
is a humanized monoclonal antibody 
(monoclonal antibodies are produced 
by a single cell and bind to the same 
region of an antigen) that blocks the 
IL-6 receptor. Originally developed for 
rheumatoid arthritis, it is recommended 
for use in CRS.15 Results of clinical trials 
to evaluate the safety and efficacy of 
tocilizumab and sarilumab in severe 
COVID-19 pneumonia are awaited. 
Box 2. Repurposing antivirals: 
Remdesivir, a drug against Ebola (also an 
RNA virus), affects RNA dependent RNA 
polymerase — an enzyme that is essential 
for RNA virus replication and protein 
synthesis.2 It is active against SARS-CoV-2, 
SARS-CoV, and MERS-CoV in laboratory 
(in vitro) tests and in animal (in vivo) 
studies. But its adverse effects include skin 
rashes, loose stools, rise in liver enzymes 
(indicating liver damage) and creatinine 
(indicating poor kidney function), and 
low blood pressure. In some cases, it 
can lead to more serious conditions, like 
multiple-organ-dysfunction syndrome, 
septic shock, and acute kidney injury.3 
The Drug Controller General of India 
(DCGI) has approved the use of remdesivir 
for emergency use to treat hospitalised 
patients with severe COVID-19.
Lopinavir-ritonavir combinations have 
been used during SARS and MERS outbreaks. 
Lopinavir, an anti-HIV drug, inhibits the 
folding of viral proteins by inhibiting the 
virus-specific enzyme aspartate protease. 
Ritonavir acts by increasing the serum 
concentration of lopinavir. Adverse effects of 
the lopinavir-ritonavir combination include 
severe skin eruptions, anaemia, lower blood 
WBC count, inflammation of the pancreas, 
and liver injury.4 The Indian Council of 
Medical Research (ICMR) advises restricted 
public health emergency use of lopinavir-
ritonavir combination therapy for severe 
COVID-19 patients.
Favipiravir, an anti-influenza drug, is 
undergoing clinical trials for treatment 
against SARS-CoV-2, especially in 
combination with drugs like chloroquine 
phosphate and tocilizumab.
Fig. 2. How does Convalescent Plasma Therapy work?
Credits: Adapted from an image by David H. Spach, University of Washington – Infectious Diseases 
Education & Assessment (IDEA) platform. URL: https://covid.idea.medicine.uw.edu/page/treatment/drugs/
human-coronavirus-immune-plasma-hcip#figures. 
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Systemic corticosteroids
Corticosteroids are steroid hormones 
that regulate inflammation and the 
immune response. Though systemic 
corticosteroids are not recommended 
for the treatment of viral pneumonia 
or ARDS, glucocorticoids such as 
methylprednisolone may be of limited 
help in severe COVID-19 induced 
ARDS. A recent study showed that 
dexamethasone, another glucocorticoid, 
reduced fever and mortality among 
critically ill COVID-19 patients.16 
However, evidence from the use of 
systemic corticosteroids in treatment of 
SARS and MERS indicates a likelihood of 
harmful side effects to the body without 
clear benefit in treating symptoms 
of infection. The Ministry of Health 
and Family Welfare, Govt. of India, 
advises the use of dexamethasone as 
an alternative to methylprednisolone in 
moderate to severe COVID-19 cases.
High-dose intravenous 
immunoglobulin (IVIg)
IVIg are polyclonal immunoglobulins 
or antibodies that are produced by 
different B cells and can bind to 
different parts of the same antigen. 
Extracted from healthy donors, IVIg is 
used in many autoimmune, infectious, 
and neuromuscular disorders for its 
immunomodulatory effects.17 Since 
it was reported to have benefits with 
tolerable side-effects in SARS and MERS 
patients, IVIg therapy is now being used 
on a case-by-case basis for COVID-19 
patients. Trials are underway to evaluate 
the efficacy of high-dose IVIg in severe 
COVID-19 patients.
Cell and biological 
therapy
Mesenchymal Stem Cells (MSCs) are stem 
cells from our bone marrow that form 
and repair skeletal tissues like bones 
and cartilages. They have been shown 
to have strong immunomodulatory 
effects. Hence, MSCs have been used for 
treatment of immune-mediated disorders 
like systemic lupus erythematosus (where 
the immune system attacks healthy 
tissue) and graft-versus-host disease 
(where the recipient of a transplant is 
attacked by cells of the graft).18 Today, 
scientists are exploring the possibility 
of using MSCs to reduce the cytokine 
storm caused by a dysfunctional immune 
response to the SARS-CoV-2 virus. One 
concern regarding this line of treatment 
is the possibility of causing adverse long-
term effects on the immune system.
Anticoagulants 
COVID-19 patients have been reported 
to have a higher incidence of venous 
thromboembolism. In this condition, 
blood clots from leg and arm veins travel 
to the lungs and cause blockage. The 
use of anticoagulants (commonly called 
blood thinners) has been associated 
with reduced ICU mortality. Hence, the 
use of anticoagulants like enoxaparin 
or heparin to prevent clot formation in 
COVID-19 is being explored.19 The World 
Health Organization (WHO) recommends 
the use of prophylactic heparin against 
venous thromboembolism in severe to 
critically ill COVID-19 patients, unless 
they are suffering from active bleeding 
or low platelet count etc. 
Parting thoughts
Finding a cure for COVID-19 is a matter 
of great urgency. But it is important 
to note that many pharmacological 
therapies that have shown potential 
need to be studied extensively, especially 
for adverse effects and their long-
term consequences. Clinical trials are 
underway in multiple countries to 
address some of these issues. The need 
of the hour is to coordinate research 
efforts across the globe for effective 
anti-SARS-CoV-2 drug design.
Box 3. Repurposing drugs against other pathogens: 
Chloroquine (CQ) and its analogue 
Hydroxychloroquine (HCQ) inhibit 
SARS-CoV-2 in vitro. HCQ is possibly the 
more potent of the two.7 Their antiviral 
mode of action is not clear, but could 
involve inhibition of pH-dependent 
steps of viral replication. They are also 
believed to act as immunomodulators, 
inhibiting tumour necrosis factor-alpha 
(TNF-α) and interleukin-6 (IL-6) — 
cytokines that in excessive amounts lead 
to hyperinflammation.8 Initial studies on 
COVID-19 patients claimed that HCQ use 
was associated with faster recovery time, 
decreased nasopharyngeal shedding of the 
virus, improved lung health, and a lower 
chance of progression to severe illness. 
These studies have been questioned due 
to their small sample sizes, lack of double 
blinding (that minimises risk of bias), and 
lack of placebo control (that eliminates the 
possibility of therapy due to psychological 
processes rather than physiological ones). 
Recent studies suggest that HCQ has no 
beneficial effects in patients hospitalized 
with COVID-19. A few preliminary studies 
even suggest that treatment with CQ/HCQ 
may be associated with similar or even 
increased risk of death, especially when 
used in combination with azithromycin.9 
In India, the ICMR has advocated the 
supervised prophylactic use of CQ/HCQ 
in high-risk populations like health care 
workers, and therapeutic use in severely ill 
COVID-19 patients.
Ivermectin, used against HIV and 
dengue viruses, acts by inhibiting the 
replication and assembly of new virions. 
In vitro studies have shown that high 
concentrations of this drug can inhibit 
SARS-CoV-2 replication.10 It has been 
suggested that combination therapy 
of ivermectin with other drugs may be 
beneficial.
Azithromycin has been shown to have 
anti-inflammatory activity in vitro and in 
clinical studies11, as well as antiviral activity 
against Zika and Ebola viruses in vitro.12 
It induces the same cytokines (like IFN-α, 
IFN-β and IFN-λ) that the body produces 
in response to viral infection and are 
known to inhibit viral replication in host 
cells.13 Preliminary studies in COVID-19 
patients have shown that azithromycin 
can influence the course of viral infection 
and clinical outcomes for the better.14 
But further studies and validation will 
be needed before its use in COVID-19 
treatment can be recommended, especially 
in combination with HCQ.
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• The immune response that SARS-CoV-2 triggers in our body is enough to resolve disease in most 
cases. Treatment is necessary only for those with severe or critical symptoms. 
• Identifying the phase of disease progression — early infection, pulmonary or hyperinflammatory 
— can help in more effective treatment. 
• Two strategies — designing new drugs, and repurposing existing drugs — are being explored to 
find drugs that can help prevent or treat COVID-19. 
• Depending on their mode of action, pharmacological approaches to COVID-19 treatment either 
target the novel virus, or help treat symptoms of the disease.
• Treatment strategies involving the use of antiviral drugs, Convalescent Plasma Therapy, and repurposed 
drugs against other pathogens are being explored for their ability to target the novel virus.
• Treatment strategies involving the use of monoclonal antibodies/IL-6 pathway inhibitors, 
corticosteroids, high-dose intravenous immunoglobulins (IVIg), cell and biological therapy, and 
anticoagulants are being explored for their ability to treat symptoms of COVID-19.
• Many promising pharmacological therapies need to be studied extensively, especially to understand 
their adverse effects and long-term consequences.
Key takeaways
